Fertility optimization in women with cancer: from preservation to contraception
| Autor: | Rui Alberto Ferriani, Paula Ctv, Jhenifer Kliemchen Rodrigues, Barreto J, Rufato Maf, Rufato Mcac, Anderson Sanches de Melo |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Infertility
medicine.medical_specialty fertility preservation Anemia media_common.quotation_subject Fertility Review oocyte freezing 03 medical and health sciences 0302 clinical medicine Neoplasms medicine Humans Fertility preservation Menstrual cycle media_common Reproductive health 030219 obstetrics & reproductive medicine business.industry Obstetrics Bone cancer Cancer medicine.disease embryo freezing Contraception 030220 oncology & carcinogenesis NEOPLASIAS Quality of Life Female infertility business |
| Zdroj: | Repositório Institucional da USP (Biblioteca Digital da Produção Intelectual) Universidade de São Paulo (USP) instacron:USP JBRA Assisted Reproduction |
| ISSN: | 1518-0557 |
| DOI: | 10.5935/1518-0557.20190011 |
| Popis: | Advances in the early diagnosis and treatment of cancer have reduced mortality rates and improved patient survival. For this reason, professionals from different areas have strived to implement actions to increase patient quality-of-life during and after cancer treatment. Among these measures, integral attention in reproductive health is one of the main points for the inclusion, safety, and autonomy of female patients. The approach to fertility in these cases should include counseling on fertility preservation and contraceptive options. Oocyte/embryo freezing is an effective technique that does not delay the start of cancer treatment, since controlled ovarian stimulation can be initiated at any stage of the menstrual cycle. At the same time, contraceptive counseling should be conducted based on the eligibility criteria established by the World Health Organization and the Centers for Disease Control and Prevention. However, there is still a lack of studies on (i) the suitability of contraceptives to patients of reproductive age with relatively frequent tumors (lymphoma, leukemia, bone cancer), and (ii) the use of contraceptive concurrently with chemotherapeutic agents. Therefore, the choice of contraceptive method should consider other factors such as tumor type, thrombogenic risk factors linked to cancer/chemotherapy, immunosuppression, blood disorders (thrombocytopenia/anemia), bone mass reduction, metabolic/cardiovascular effects, and drug interaction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|